Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 41 - 50 of 333

<< Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next >>

Last updated: 20th February 2008

Patent No.: US 172945
Human neutrophil alpha-defensin 4 inhibition of HIV-1.
Applicant: Lu W, Cocchi F, Wu Z (2006)
A method to reduce replication of HIV-1, involving administering a therapeutically effective amt. of recombinant HNP4 to a subject in need thereof to combat HIV-1 infection. The HNP4 agent may be utilized in pharmaceutical compns. including a pharmaceutically acceptable carrier and an anti-viral agent, e.g., an anti-viral agent, or combination of such agents, such as nucleoside RT inhibitors, CCR5 inhibitors/antagonists, viral entry inhibitors, and functional analogs thereof.

Patent No.: US 147442
Fusion products of biocides including phospholipase A2 for neutralization of Cryptosporidium parvum.
Applicant: Homan J, Imboden M, Riggs M, Carryn S, Schaefer DA (2006)
The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant prodn.), and food processing (e.g., water purifn.). Active portions of lactoferrin hydrolyzate, lactoferrin b, cathelicidin, indolicidin, beta-defensin-2, beta-defensin-1, phospholipase A2, and phosphoinositol-specific phospholipase C are shown to neutralize Cryptosporidium parvum sporozoites. In addn., constructs are provided that encode novel microorganism targeting mols. (e.g., innate immune receptor ligands or monoclonal antibodies), novel fusion proteins, and chimeric monoclonal antibodies. Monoclonal antibody biocide (e.g., bactericidal enzymes) fusion proteins are produced in transgenic animals and cell cultures. In particular, sol. CD14, LBP (lipopolysaccharide-binding protein), SP-D (surfactant protein D), MBS (mannan-binding lectin), and monoclonal antibody 3H2 specific for GP25-200 target, are engineered into a retrovirus backbone for secretion as fusion proteins with human phospholipase A2.

Patent No.: US 074020
Inhibition of angiogenesis by neutrophil alpha-defensins.
Applicant: Cines D, Bdeir K, Chavakis T, Preissner KT (2006)
The present invention relates to the inhibition of angiogenesis by neutrophil alpha-defensins. Further, the present invention relates to methods involving the inhibition of endothelial cell adhesion to the extracellular matrix, endothelial cell apoptosis, and endothelial cell angiogenesis mediated by alpha-defensins. b) instructions for the use of said alpha-defensin for the purpose of modulating a biol. process assocd. with said endothelial cell.

Patent No.: US 057654
Use of the concentration of alpha-defensins HNP 1, HNP 2, and HNP 3 in human saliva as a marker of the susceptibility to dental caries.
Applicant: Dale-Crunk BA, Kimball JR, Tao R (2006)
The present invention provides methods for detg. whether a human being is susceptible to dental caries. The present inventors have discovered that the total amt. of three alpha-defensin peptides HNP 1, HNP 2 and HNP 3, in saliva correlate with the susceptibility of a human being to dental caries. The methods each include the steps of measuring the amt. of alpha-defensins HNP 1, HNP 2 and HNP 3 in saliva obtained from a human being, and detg. whether a reduced amt. of the alpha-defensins HNP 1, HNP 2 and HNP 3 is present in the saliva, thereby detg. whether the human being is susceptible to dental caries. A reduced amt. of alpha-defensins HNP 1, HNP 2, and HNP 3 in the saliva indicates susceptibility of the human being to dental caries.

Patent No.: US 037100
Sequences of Capsicum annuum defensin and esterase genes and use for generating fungal resistant transgenic pepper plants.
Applicant: Kim YS, Ko MK, Seo HH, Cho JH, Song P-S (2006)
The invention provides sequences of Capsicum annuum defensin and esterase genes for stable pepper transformation using Agrobacterium mediated method. Pepper plants were transformed with PepEST or PepDef gene, where the expression of the nucleic acid sequence in the plant resulted in increased resistance to fungal infection as compared to the wild type plant. Provided are agricultural products including seeds produced by the transgenic plants. Also provided are vectors and host cells contg. the nucleic acids coding PepEST and PepDef, resp.

Patent No.: US 034820
Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.
Applicant: Lim DJ, Lee H-Y, Webster P, Andalibi A, Li J-D, Ganz T, Cha K (2006)
Disclosed herein is a compn. and a method for the treatment of infectious diseases such as otitis media, paranasal sinusitis, labyrinthitis, and meningitis using human defensins, lysozyme and/or lactoferrin as a new class of non-antibiotic antimicrobials. From studies of otitis media and paranasal sinusitis, it was obsd. that certain innate immune modulators were important in the body's response to the infection. Therefore, these innate immune modulators, lysozyme, lactoferrin, and defensins were tested for use as a non-antibiotic treatment for infection, particularly infections such as otitis media and sinusitis. The defensins can be alpha-defensins or beta-defensins such as beta-defensin 1, beta-defensin 2 and EP2E.

Patent No.: WO 115520
Methods, systems and devices for noninvasive pulmonary drug delivery.
Applicant: Niven R, Watanabe W, Thomas M, Brown D, Johnson M, Rairkar M (2005)
The invention is directed to noninvasive methods, systems and devices for pulmonary delivery of aerosolized active agents and methods of treating respiratory dysfunction. Thus, 16-25% of aerosolized KL4 lung surfactant was deposited in the lungs in healthy humans. KL4 is a 21 mer cationic peptide.

Patent No.: WO 115403
Induction of innate immunity by vitamin D3 and its analogs.
Applicant: Gombart AF, Koeffler HP (2005)
Cationic antimicrobial peptides (AMPs) are an integral part of the innate immune system. Cathelicidin and defensin homologs from a variety of species exhibit broad-range bactericidal activity. The human cathelicidin analog, hCAP18, is encoded by the CAMP gene. Vitamin D3 and its analogs upregulate transcription of CAMP and defensin .beta.2 (defB2) genes, leading to increased expression of hCAP18 mRNA and defB2. Induction of CAMP was obsd. in acute myeloid leukemia (AML), immortalized keratinocyte and colon cancer cell lines, as well as normal human bone marrow (BM)-derived macrophages and fresh BM cells. The present invention provides methods of inducing cathelicidin prodn. by administering Vitamin D3 or Vitamin D3 analogs, as well as methods of treating skin infections and infections of the colon, sepsis and wound healing, preventing bacterial growth on skin grafts, promoting angiogenesis, and promoting chemoattraction by administering Vitamin D3 or Vitamin D3 analogs to upregulate cathelicidin and defensin expression.

Patent No.: WO 094579
Synergistic antimicrobial compositions for reducing biofilm formation.
Applicant: Madhyastha S (2005)
The invention provides compns. comprising a thiol-specific reagent combined with a cationic polypeptide, an iron-sequestering glycoprotein or a quaternary ammonium compd., usable as synergistic antimicrobial compns. for reducing biofilm formation, in particular on medical devices.

Patent No.: WO 084635
Pharmaceutical preparations for and treatment of dry eye conditions and other disorders.
Applicant: Daniels J, Watson S, Geerling G, Dart J (2005)
The present invention relates to pharmaceutical prepns. and their use in the treatment and/or prophylaxis of dry eye conditions and other ocular surface disorders. Specifically, the pharmaceutical prepn. comprises: (i) a pharmaceutically acceptable carrier suitable for use in the eye; (ii) one or more ingredients selected from factors and agents that promote any one or more of survival, health, cell attachment and normal differentiation of ocular surface epithelial cells and optionally factors and agents to prevent squamous metaplasia; (iii) one or more agents capable of altering the fluid properties of a tear film including at least one agent capable of establishing and/or maintaining a stable tear film and optionally one or more agents selected from ophthalmol. lubricating agents, viscosity enhancing agents and agents capable of reducing tear film evapn.; the factors and agents in component (ii) and (iii) being synthetic or recombinant or licensed for pharmaceutical use.